News

January 4, 2017

Surface Oncology Welcomes Industry Leader Daniel S. Lynch as Chairman of Board of Directors

Surface Oncology, an immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of industry leader Daniel S. Lynch, as Executive Chairman of the company’s Board of Directors. Mr. Lynch’s appointment brings additional industry leadership experience to the Board as the company advances its pipeline of next-generation immunotherapies towards the clinic. Mr. Lynch will succeed Dr. David Grayzel, a co-founder of Surface Oncology who has served as Chairman since the company was formed. Dr. Grayzel will continue as a member of the Board.

 

With over 25 years of industry experience, Mr. Lynch has advised and served as Chairman or Board member for a number of top tier biotechnology companies. He currently serves on the Boards of several biotech companies, including Bluebird Bio, RaNA Therapeutics, and BluePrint Medicines. He previously served on the Boards of a range of additional companies, including Nimbus Therapeutics, Avila Therapeutics, and Stromedix. Over the course of his career, Mr. Lynch has successfully helped to guide multiple biotech companies through their entry into the public markets.

Read More

Back to News